Catalent (CTLT)
(Delayed Data from NYSE)
$55.80 USD
-0.15 (-0.27%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $55.80 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
CTLT 55.80 -0.15(-0.27%)
Will CTLT be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CTLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTLT
TAK or CTLT: Which Is the Better Value Stock Right Now?
Charles River (CRL) Forges Collaboration With Ship of Theseus
CTLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down
Other News for CTLT
Goldman’s debt issuers stocks basket
Laughing Water Capital Q1 2024 Letter
Analysts Offer Insights on Healthcare Companies: Catalent (CTLT), Vertex Pharmaceuticals (VRTX) and Alkermes (ALKS)
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Healthcare M&A Volume Falls in Q1:24, According to Acquisition Data from LevinPro HC